Fig. 2.

Future perspectives of biomarker for immune checkpoint blockade therapy. It is expected that more accurate prediction of clinical benefits and/or adverse events will be realized by comprehensive integration of multiparametric biomarkers for individual patients, containing histological and cytometric examination and genetic analysis of tumor cell and non-tumor cells. In that process, artificial intelligence would play a crucial role in the scoring procedure for the selection of optimal patients or therapy